# Advion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/advion

- Industry: Biotechnology
- Headquarters: Ithaca, US
- Website: www.advion.com
- Total disclosed funding: $32M
- Latest round: Series B (May 29, 2008)
- Investors on record: 7

## About

Advion, Inc. is a leading provider of advanced mass spectrometry solutions, catering to academic, pharmaceutical, and clinical markets with a focus on innovation and efficiency in laboratory processes.Founded in 1993 and headquartered in Ithaca, US, Advion, Inc. specializes in mass spectrometry solutions. The company has successfully secured funding through a Series B round of USD 0.180 mn from Polaris Partners, bringing their total amount raised to USD 0.180 mn, with a current company valuation of USD 62.179 mn. The management team includes CEOs Jamey Jones and Kaveh Kahen.Advion Interchim Scientific develops and manufactures advanced mass spectrometry solutions for various applications. Their key products include the ex press ion® Compact Mass Spectrometer (CMS), the AVANT™ (U)HPLC, and the SOLATION® ICP-MS, which enhance laboratory efficiency and facilitate rapid data analysis for chemists in academic, pharmaceutical, and biopharmaceutical settings, serving markets across North America, Europe, and parts of Asia.Advion Interchim Scientific generates revenue through direct sales and B2B partnerships, focusing on specialized mass spectrometry tools. Revenue streams include sales of products such as the ex press ion® CMS and SOLATION® ICP-MS, alongside service agreements for maintenance and support, targeting researchers and laboratories in chemical analysis and biopharmaceutical applications.Advion, Inc. is actively designing new products for future launches, aiming to expand their market reach into additional geographic regions, including Asia and Europe, by the end of 2024. The recent funding from the Series B round will support these product development initiatives and market expansion efforts. Additionally, Quintiles Transnational Corporation, a portfolio company of 3i, previously exited its stake in Advion, although financial terms were not disclosed.

## Funding rounds

- Series B, May 29, 2008, $0.2M — Polaris Partners
- Series E, Dec 11, 2007, $9.1M — Polaris Partners, Skyline Ventures, Aisling Capital, Credit Suisse
- Series B, Aug 6, 2007, $8.1M — Polaris Partners, Skyline Ventures, Aisling Capital, Cayuga Venture Fund, Credit Suisse Innoventure Capital AG
- Series B, May 7, 2002, $15M — TowerBrook, Polaris Partners, Skyline Ventures, Aisling Capital

## Investors

- TowerBrook (https://capitalatlas.ai/funds/towerbrook) — Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B, Series E
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series B, Series E
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B, Series E
- Cayuga Venture Fund (https://capitalatlas.ai/funds/cayuga-venture-fund) — Series B
- Credit Suisse Innoventure Capital AG (https://capitalatlas.ai/funds/credit-suisse-innoventure-capital-ag) — Series B
- Credit Suisse (https://capitalatlas.ai/funds/credit-suisse) — Series E